Corticosteroid Usage in Giant Cell Arteritis

Amritha Kanakamedala, Mariam Hussain, Ashwini Kini, Bayan Al Othman, Andrew G. Lee

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Giant cell arteritis (GCA) is a condition that can cause irreversible visual loss if untreated. While corticosteroids remain the mainstay of treatment to prevent visual loss, the type, dose, route, and duration of corticosteroid treatment of GCA remain controversial. Our study surveyed neuro-ophthalmologists to determine commonly prescribed dosages of corticosteroids for the treatment of GCA with or without visual loss. For patients with acute visual loss, 52% would use intravenous (IV), 46% would use IV or oral and 2% would use oral corticosteroids. Seventy-three per cent would use 500 to 1000 mg IV methylprednisolone in this group. For patients with GCA without acute visual loss, 67% would use the oral route, 30% would use IV or oral, and 3% indicated they would use IV route of treatment. Seventy-five per cent would use 1.0 to 1.5 mg/kg oral prednisone in this group. Our results suggest a majority but not a complete consensus for route and dose of corticosteroid treatment in GCA and confirm conventional recommendations for high dose IV corticosteroids for GCA with visual loss and lower dose oral regimens for GCA without visual loss.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
StateE-pub ahead of print - Jul 16 2020


  • Giant Cell Arteritis
  • corticosteroid
  • dosage
  • vasculitis
  • vision Loss

ASJC Scopus subject areas

  • Ophthalmology
  • Clinical Neurology


Dive into the research topics of 'Corticosteroid Usage in Giant Cell Arteritis'. Together they form a unique fingerprint.

Cite this